The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG
- Author:
Eiji KONDO
1
;
Tsutomu TABATA
;
Nao SUZUKI
;
Daisuke AOKI
;
Hideaki YAHATA
;
Yoshio KOTERA
;
Osamu TOKUYAMA
;
Keiichi FUJIWARA
;
Eizo KIMURA
;
Fumitoshi TERAUCHI
;
Toshiyuki SUMI
;
Aikou OKAMOTO
;
Nobuo YAEGASHI
;
Takayuki ENOMOTO
;
Toru SUGIYAMA
Author Information
- Publication Type:Original Article
- From:Journal of Gynecologic Oncology 2020;31(6):e94-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:In this study we sought to investigate the clinical factors that affect postprogression survival (PPS) in patients with recurrent or persistent clear cell carcinoma (CCC).We utilized the JGOG3017/Gynecological Cancer InterGroup data to compare paclitaxel plus carboplatin (TC) and irinotecan plus cisplatin (CPT-P) in the treatment of stages I to IV CCC.
Methods:We enrolled 166 patients with recurrent or persistent CCC and assessed the impact of variables, including platinum sensitivity, treatment arm, crossover chemotherapy, primary stage, residual tumor at primary surgery, performance status, ethnicity, and tumor reduction surgery at recurrence on the median of PPS in patients with recurrent or persistent CCC.
Results:A total of 77 patients received TC, and 89 patients received CPT-P. The median PPS for patients with platinum-resistant disease was 10.9 months, compared with 18.8 months for patients with platinum-sensitive disease (hazard ratio [HR]=1.88; 95% confidence interval [CI]=1.30–2.72; log-rank p<0.001). In the multivariate analysis, the platinum sensitivity (resistant vs. sensitivity; HR=1.60; p=0.027) and primary stage (p=0.009) were identified as independent predictors of prognosis factors for PPS in recurrent or persistent CCC.
Conclusions:Our findings revealed that platinum sensitivity and primary stage are clinical factors that significantly affect PPS in patients with recurrent or persistent CCC as wellas other histologic subtypes of ovarian cancer. PPS in patients with recurrent CCC should establish the basis for future clinical trials in this population.
